Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
June 07, 2024 20:18 ET
|
Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
June 06, 2024 08:00 ET
|
Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
June 03, 2024 11:00 ET
|
Biolojic Design
Biolojic Design Enters into Multi-Target Drug Discovery Collaboration
with Merck KGaA, Darmstadt, Germany in oncology and immunology
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
May 23, 2024 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
[Latest] Global Non-Small-Cell Lung Cancer Drug Market Size/Share Worth USD 68,888.6 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 21, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
May 09, 2024 09:00 ET
|
Curia Global, Inc.
The symposium, Unlocking High-Throughput Biology in Drug Discovery, will take place on May 31 in Seattle and feature industry-leading scientists.
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
May 09, 2024 07:30 ET
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
Avid Bioservices to Participate at Upcoming Investor Conferences
May 07, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly and Company, Merck Sharp & Dohme LLC, T
May 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
April 24, 2024 17:25 ET
|
Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion...